MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Maxim reduces PTs in challenging biotech market
Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...
Cantor starts Pliant Therapeutics at OW; PT $12
Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...
Know Labs adds CFO, CPO to leadership team
Peter Conley and Steven Kent joined the leadership team at Know Labs (OTCQB:KNWN) as chief financial officer and chief product officer, respectively. Mr. Conley also takes on the position of SVP, intellectual property...
Cantor starts Lyra Therapeutics at OW; PT $15
Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...
MindMed names Schond Greenway as CFO
Schond Greenway Mind Medicine (NASDAQ:MNMD; NEO:MMED) appointed Schond Greenway as CFO. He comes to MindMed with more than 20 years of experience in investment banking, finance and corporate advisory, and investment...
Analysts start HilleVax at buy, outperform
Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...
Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022
“We continue to gain confidence in the disruptive potential of Profound Medical’s (NASDAQ:PROF; TSX:PRN) transurethral directional thermal ultrasound ablation treatment for prostate cancer, TULSA-PRO,” writes Cowen...
MindMed reports Phase 1 topline data with MM-110 in opioid withdrawal
Mind Medicine (NASDAQ:MNMD; NEO:MMED) reported favorable safety and tolerability results from a Phase 1 placebo-controlled trial designed to assess safety, tolerability, pharmacokinetics and neurocognitive effects of MM...
Profound Medical insiders add to holdings
Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...
Profound Medical’s TULSA-PRO front and center at AUA2022
The American Urological Association’s 2022 annual meeting featured multiple clinical presentations and product demonstrations of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO to effectively and safely ablate...
Ampio board committee conducting internal investigation
An independent special committee of the board of Ampio Pharmaceuticals (NYSE American:AMPE), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to...
Soricimed Biopharma adds deep public markets experience to team with appointment of healthcare veteran Frank Michalargias as CFO
Frank Michalargias Closely-held Soricimed Biopharma, an oncology drug developer, appointed healthcare industry veteran Frank Michalargias as CFO. In a finance and operations leadership career spanning more than 25...
Just a few of the companies we’ve highlighted along the way
